Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes

被引:80
作者
McNeish, IA [1 ]
Bell, SJ [1 ]
Lemoine, NR [1 ]
机构
[1] Hammersmith Hosp, Canc Res UK, Mol Oncol Unit, Imperial Coll Sch Med, London W12 0HS, England
关键词
tumour suppressor gene; p53; Rb; PTEN; cinical trial;
D O I
10.1038/sj.gt.3302238
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Targeting tumour suppressor gene pathways is an attractive therapeutic strategy in cancer. Since the first clinical trial took place in 1996, at least 20 other trials have investigated the possibility of restoring p53 function, either alone or in combination with chemotherapy, but with limited success. Other recent clinical trials have sought to harness abnormalities in the p53 pathway to permit tumour-selective replication of adenoviral vectors such as dl1520 (Onyx-015). Other tumour suppressor genes, such as retinoblastoma (Rb) and PTEN (phosphatase, tensin homologue, deleted on chromosome 10), are the targets for imminent clinical trials, while microarray technologies are revealing multiple new genes that are potential targets for future gene therapy.
引用
收藏
页码:497 / 503
页数:7
相关论文
共 70 条
[1]  
Abe T, 2003, CANCER RES, V63, P2300
[2]  
Bauerschmitz GJ, 2002, CANCER RES, V62, P1266
[3]   p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis [J].
Bergamaschi, D ;
Gasco, M ;
Hiller, L ;
Sullivan, A ;
Syed, N ;
Trigiante, G ;
Yulug, I ;
Merlano, M ;
Numico, G ;
Comino, A ;
Attard, M ;
Reelfs, O ;
Gusterson, B ;
Bell, AK ;
Heath, V ;
Tavassoli, M ;
Farrell, PJ ;
Smith, P ;
Lu, X ;
Crook, T .
CANCER CELL, 2003, 3 (04) :387-402
[4]   The role of adenovirus E4orf4 protein in viral replication and cell killing [J].
Branton, PE ;
Roopchand, DE .
ONCOGENE, 2001, 20 (54) :7855-7865
[5]   A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer [J].
Buller, RE ;
Runnebaum, IB ;
Karlan, BY ;
Horowitz, JA ;
Shahin, M ;
Buekers, T ;
Petrauskas, S ;
Kreienberg, R ;
Slamon, D ;
Pegram, M .
CANCER GENE THERAPY, 2002, 9 (07) :553-566
[6]  
Claudio PP, 2000, CANCER RES, V60, P372
[7]  
Davies MA, 2002, CLIN CANCER RES, V8, P1904
[8]   Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function [J].
de Vries, A ;
Flores, ER ;
Miranda, B ;
Hsieh, HM ;
van Oostrom, CTM ;
Sage, J ;
Jacks, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (05) :2948-2953
[9]   Recombinant adenovirus-mediated p14ARF overexpression sensitizes human breast cancer cells to cisplatin [J].
Deng, XY ;
Kim, M ;
Vandier, D ;
Jung, YJ ;
Rikiyama, T ;
Sgagias, MK ;
Goldsmith, M ;
Cowan, KH .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 296 (04) :792-798
[10]   Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway? [J].
Dix, BR ;
Edwards, SJ ;
Braithwaite, AW .
JOURNAL OF VIROLOGY, 2001, 75 (12) :5443-5447